Up next

Autoplay

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

2 Views • 07/14/23
Share
Embed
administrator
administrator
Subscribers
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay